Larimar Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Carole Ben-Maimon

Chief Executive Officer (CEO)

US$3.1m

Compensación total

Porcentaje del salario del CEO	17.8%
Permanencia del CEO	4yrs
Participación del CEO	0.2%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Carole Ben-Maimon en comparación con los beneficios de Larimar Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$3m	US$560k	-US$37m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$2m	US$528k	-US$35m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$510k	-US$51m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$49m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$5m	US$268k	-US$42m

Compensación vs. Mercado: La compensación total ($USD3.14M) de Carole está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.43M).

Compensación vs. Ingresos: La compensación de Carole ha aumentado mientras la empresa no es rentable.

CEO

Carole Ben-Maimon (64 yo)

4yrs

Permanencia

US$3,137,432

Compensación

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Carole Ben-Maimon	CEO, President & Director	4yrs	US$3.14m	0.18% $ 888.8k
Michael Celano	Secretary & CFO	4yrs	US$1.42m	0.087% $ 438.2k
Gopi Shankar	Chief Development Officer	1.3yrs	US$1.43m	0.0078% $ 39.3k
John Berman	Vice President of Finance & Administration	less than a year	sin datos	sin datos
Jennifer Johansson	Vice President of Legal & Compliance	7.4yrs	sin datos	sin datos
Russell Clayton	Chief Medical Officer	less than a year	sin datos	sin datos
Francis Conway	VP & Controller	3.8yrs	sin datos	sin datos

3.8yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de LRMR se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Carole Ben-Maimon	CEO, President & Director	4yrs	US$3.14m	0.18% $ 888.8k
Jonathan Leff	Independent Director	4yrs	US$79.96k	sin datos
Jeffrey Sherman	Independent Director	less than a year	US$56.43k	0% $ 0
Frank Thomas	Independent Director	9.9yrs	US$86.21k	0.0031% $ 15.7k
Thomas Hamilton	Independent Director	4yrs	US$77.77k	0.89% $ 4.4m
Joseph Truitt	Independent Chairman of the Board	4yrs	US$114.96k	0.0043% $ 21.6k
Giovanni Manfredi	Member of Scientific Advisory Board	3.6yrs	sin datos	sin datos
Mark Payne	Member of Scientific Advisory Board	3.6yrs	sin datos	sin datos
Marni Falk	Member of Scientific Advisory Board	3.6yrs	sin datos	sin datos
Jill Ostrem	Member of Scientific Advisory Board	1.7yrs	sin datos	sin datos

3.8yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de LRMR se considera experimentada (3.7 años de antigüedad promedio).

Larimar Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought US$100k worth of stock

High number of new and inexperienced directors

Recent updates

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad